Praxis Precision Medicines, Inc. PRAX

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan

Praxis Precision Medicines reported its second-quarter 2026 results, posting a net loss of US$83.72 million and basic loss per share from continuing operations of US$2.87, while reaffirming its focus on central nervous system therapies. Alongside widening year-to-date losses, the company highlighted progress on key drug candidates such as ulixacaltamide and relutrigine, supported by a US$1.40 billion cash position that funds operations into 2028. With this mix of heavier losses and robust...

Moby summary of Praxis Precision Medicines, Inc.'s Q2 2026 earnings call

Praxis Precision Medicines Inc (PRAX) reports strong regulatory progress for ulixacaltamide and relutrigine, while addressing the POWER1 miss and preparing for commercial launches.

Insmed stock led a biotech rally Thursday, catapulting 34% on solid second-quarter sales for its new lung disease drug, Brinsupri.

Delcath Systems announced a return to profitability after posting losses in the past two quarters, while Praxis’ second-quarter loss came in narrower than Wall Street had expected

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027 Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026 FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine comp

BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the second quarter ended June 30, 2026 and provide a corporate update, before the financial markets open on Thursday, August 6, 2026. The Company will host a conference call and a live webcast to review the second quarter financial results and p

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 affordable biotech stocks to buy right now. On July 7, Praxis Precision Medicines Inc. (NASDAQ:PRAX) and Remagine Labs disclosed a research partnership and license agreement to design an iontophoretic transdermal patch for the delivery of ulixacaltamide. Ulixacaltamide is a strongly targeted T-type calcium channel inhibitor […]

Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route Potential to expand the addressable market for ulixacaltamide beyond the initial patient population and to enable additional life-cycle management opportunities Praxis to make equity investment in Remagine Labs, accelerating the companies' collaboration BOSTON, Mass. and AUSTIN, Texas, July 07, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated central nervou

FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) notified Praxis that it has extended by three months the review period for its New Drug Application (NDA) for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic e

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) shares climbed 4% on Monday after the company announced that the U.

The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizures (p=0.015), with benefit sustained in the open-label extension for up to one year The pivotal EMBRAVE3 study is enrolling under a streamlined, single-arm registrational pathway aligned with the FDA Elsunersen now holds Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease Designations from